Intravitreal Bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration

• Verfasst von: Ach, Thomas [VerfasserIn]
• Verfasst von: Höh, Alexandra E. [VerfasserIn]
• Verfasst von: Ruppenstein, Mira Katharina [VerfasserIn]
• Verfasst von: Kretz, Florian T. A. [VerfasserIn]
• Verfasst von: Dithmar, Stefan [VerfasserIn]
• Titel: Intravitreal Bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration
• Verf.angabe: Thomas Ach, Alexandra E. Hoeh, Mira Ruppenstein, Florian T.A. Kretz, Stefan Dithmar
• E-Jahr: 2010
• Jahr: October 2010
• Umfang: 6 S.
• Fussnoten: Gesehen am 15.11.2022
• Titel Quelle: Enthalten in: Retina
• Ort Quelle: Philadelphia, Pa. [u.a.] : Lippincott, Williams & Wilkins, 1981
• Jahr Quelle: 2010
• Band/Heft Quelle: 30(2010), 9, Seite 1420-1425
• ISSN Quelle: 1539-2864
• DOI: doi:10.1097/IAE.0b013e3181d87e97
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1822513022

Abstract

Purpose: - The purpose of this study was to evaluate the effect of intravitreally administered bevacizumab on untreated vascularized pigment epithelium detachment (PED) in sub- or juxtafoveal occult choroidal neovascularization as a result of age-related macular degeneration. - Methods: - In this retrospective study, 28 untreated eyes of 26 patients (4 men, 22 women; mean age, 74.6 ± 7.2 years) with PED and sub- or juxtafoveal occult choroidal neovascularization as a result of age-related macular degeneration and additional intra- and/or subretinal fluid were treated with intravitreal injections of 1.25 mg bevacizumab. Baseline and follow-up visits included best-corrected visual acuity, complete ophthalmic examination, and Stratus optical coherence tomography. Fluorescein angiography was performed at baseline. Reinjections were performed if intra- and/or subretinal fluid persisted or recurred or PED increased. - Results: - Patients received 3.2 ± 1.8 injections (follow-up 37.9 ± 18.3 weeks). Mean maximum PED height showed a tendency to decrease (372 ± 150.5 μm to 290.3 ± 189 μm; P = 0.094). In 14 eyes (53.8%), PED height was reduced at last visit, including complete flattening in 1 eye. Mean visual acuity remained stable (0.58 ± 0.30 logarithm of the minimum angle of resolution to 0.58 ± 0.37 logarithm of the minimum angle of resolution; P = 0.905). Pigment epithelium detachment response to treatment did not correlate with baseline PED height or visual acuity at baseline or at the last visit. One patient sustained a retinal pigment epithelium rip, and another patient sustained an extensive subretinal hemorrhage. - Conclusion: - During bevacizumab therapy, mean PED height decreases in 50% of patients. No predictive factors for the response of PED to bevacizumab treatment could be identified. Treatment of PED with bevacizumab might result in a long-term functional benefit compared with the natural course.